Vistagen provides corporate update and reports fiscal 2023 third quarter financial results

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended december 31, 2022.
VTGN Ratings Summary
VTGN Quant Ranking